biguanides has been researched along with Keratitis, Acanthamoeba in 107 studies
Biguanides: Derivatives of biguanide (the structure formula HN(C(NH)NH2)2) that are primarily used as oral HYPOGLYCEMIC AGENTS for the treatment of DIABETES MELLITUS, TYPE 2 and PREDIABETES.
biguanides : A class of oral hypoglycemic drugs used for diabetes mellitus or prediabetes treatment. They have a structure based on the 2-carbamimidoylguanidine skeleton.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Outcomes were similar when using PHMB and chlorhexidine as monotherapy agents in treating Acanthamoeba keratitis." | 9.13 | Comparison of polyhexamethylene biguanide and chlorhexidine as monotherapy agents in the treatment of Acanthamoeba keratitis. ( Bunce, C; Ficker, L; Fraenkel, G; Goh, D; Lim, N; Poole, TR; Xing, W, 2008) |
| "To report a case series of patients with treatment-resistant Acanthamoeba keratitis (AK) using oral miltefosine, often as salvage therapy." | 8.02 | Oral Miltefosine as Salvage Therapy for Refractory Acanthamoeba Keratitis. ( Appenheimer, AB; Chodosh, J; Hou, JH; Kang, JJ; Morrill, AM; Rapuano, CJ; Saeed, HN; Thulasi, P; Tu, EY; Vyas, N; Zegans, ME; Zuckerman, R, 2021) |
| "In this study, a series of compounds - miltefosine, polyhexamethylene biguanide, chlorhexidine and propamidine isethionate - and combinations of the latter three agents with miltefosine were prepared and used in a rat model for the topical treatment of Acanthamoeba keratitis." | 7.80 | Miltefosine and polyhexamethylene biguanide: a new drug combination for the treatment of Acanthamoeba keratitis. ( Arici, MK; Dursun, A; Obwaller, A; Polat, ZA; Vural, A; Walochnik, J, 2014) |
| "To assess dose- and concentration-dependent rates of biguanides on the viability of Acanthamoeba cysts isolated from severe ulcerative keratitis, and to correlate cysticidal activites with cytotoxic profiles in corneal and endothelial cells." | 7.79 | Antimicrobial action of biguanides on the viability of Acanthamoeba cysts and assessment of cell toxicity. ( Carrijo-Carvalho, LC; Carvalho, FR; Chudzinski-Tavassi, AM; de Freitas, D; Foronda, AS; Mafra, CS; Taguchi, FM, 2013) |
| "To present the first 3 cases of Acanthamoeba keratitis (AK), unresponsive to medical treatment, that were successfully treated with a novel adjunctive therapy using ultraviolet light A (UVA) and riboflavin (B2)." | 7.77 | Riboflavin and ultraviolet light a therapy as an adjuvant treatment for medically refractive Acanthamoeba keratitis: report of 3 cases. ( Behrens, A; Castro-Combs, JM; Flikier, D; Kalyani, S; Kashiwabuchi, RT; Khan, YA; Martins, SA; Stanley, P, 2011) |
| " We report cases of combined Fusarium and Acanthamoeba keratitis and the clinical course of medical treatment." | 7.75 | Medical treatment for combined Fusarium and Acanthamoeba keratitis. ( Hsiao, CH; Huang, SC; Lin, HC; Lin, MY; Ma, DH; Tan, HY; Yeh, LK, 2009) |
| "To report patients with acanthamoeba keratitis treated with the association of propamidine (Brolene) and polyhexamethylbiguanide (PHMB) 0." | 7.71 | [Acanthamoeba keratitis treated with propamidine and polyhexamethyl biguanide (PHMB)]. ( Donoso, R; López, M; Mura, JJ, 2002) |
| "02% chlorhexidine for the treatment of Acanthamoeba keratitis (AK)." | 5.41 | A randomized masked pilot clinical trial to compare the efficacy of topical 1% voriconazole ophthalmic solution as monotherapy with combination therapy of topical 0.02% polyhexamethylene biguanide and 0.02% chlorhexidine in the treatment of Acanthamoeba k ( Bagga, B; Garg, P; Gour, RPS; Joseph, J; M Rathi, V; Mohamed, A; Sharma, S, 2021) |
| "Acanthamoeba keratitis is a painful corneal infection and difficult to treat because no sufficiently efficient drug has yet been available." | 5.38 | Efficacy of miltefosine for topical treatment of Acanthamoeba keratitis in Syrian hamsters. ( Obwaller, A; Polat, ZA; Vural, A; Walochnik, J, 2012) |
| "Outcomes were similar when using PHMB and chlorhexidine as monotherapy agents in treating Acanthamoeba keratitis." | 5.13 | Comparison of polyhexamethylene biguanide and chlorhexidine as monotherapy agents in the treatment of Acanthamoeba keratitis. ( Bunce, C; Ficker, L; Fraenkel, G; Goh, D; Lim, N; Poole, TR; Xing, W, 2008) |
| "The treatment of Acanthamoeba keratitis has now been possible since the first successful therapy developed in the mid 1980s with a combination of propamidine 0." | 4.82 | Treatment of Acanthamoeba keratitis. ( Seal, D, 2003) |
| "To report a case series of patients with treatment-resistant Acanthamoeba keratitis (AK) using oral miltefosine, often as salvage therapy." | 4.02 | Oral Miltefosine as Salvage Therapy for Refractory Acanthamoeba Keratitis. ( Appenheimer, AB; Chodosh, J; Hou, JH; Kang, JJ; Morrill, AM; Rapuano, CJ; Saeed, HN; Thulasi, P; Tu, EY; Vyas, N; Zegans, ME; Zuckerman, R, 2021) |
| "In this study, a series of compounds - miltefosine, polyhexamethylene biguanide, chlorhexidine and propamidine isethionate - and combinations of the latter three agents with miltefosine were prepared and used in a rat model for the topical treatment of Acanthamoeba keratitis." | 3.80 | Miltefosine and polyhexamethylene biguanide: a new drug combination for the treatment of Acanthamoeba keratitis. ( Arici, MK; Dursun, A; Obwaller, A; Polat, ZA; Vural, A; Walochnik, J, 2014) |
| "To assess dose- and concentration-dependent rates of biguanides on the viability of Acanthamoeba cysts isolated from severe ulcerative keratitis, and to correlate cysticidal activites with cytotoxic profiles in corneal and endothelial cells." | 3.79 | Antimicrobial action of biguanides on the viability of Acanthamoeba cysts and assessment of cell toxicity. ( Carrijo-Carvalho, LC; Carvalho, FR; Chudzinski-Tavassi, AM; de Freitas, D; Foronda, AS; Mafra, CS; Taguchi, FM, 2013) |
| "To present the first 3 cases of Acanthamoeba keratitis (AK), unresponsive to medical treatment, that were successfully treated with a novel adjunctive therapy using ultraviolet light A (UVA) and riboflavin (B2)." | 3.77 | Riboflavin and ultraviolet light a therapy as an adjuvant treatment for medically refractive Acanthamoeba keratitis: report of 3 cases. ( Behrens, A; Castro-Combs, JM; Flikier, D; Kalyani, S; Kashiwabuchi, RT; Khan, YA; Martins, SA; Stanley, P, 2011) |
| " We report cases of combined Fusarium and Acanthamoeba keratitis and the clinical course of medical treatment." | 3.75 | Medical treatment for combined Fusarium and Acanthamoeba keratitis. ( Hsiao, CH; Huang, SC; Lin, HC; Lin, MY; Ma, DH; Tan, HY; Yeh, LK, 2009) |
| " Six others had the abrupt onset of a dense cataract, including 5 with iris atrophy, that occurred during the initial 6 months of therapy with chlorhexidine, a diamidine, and adjunctive corticosteroid." | 3.74 | Rapidly progressive cataract and iris atrophy during treatment of Acanthamoeba keratitis. ( Herz, NL; Matoba, AY; Wilhelmus, KR, 2008) |
| "In our large series of Acanthamoeba keratitis with a positive microbiologic diagnosis at presentation, nearly 5% developed recurrent episodes of corneal and scleral inflammation with viable Acanthamoeba in the cornea despite prolonged treatment with biguanides and/or diamidines." | 3.72 | Persistently culture positive acanthamoeba keratitis: in vivo resistance and in vitro sensitivity. ( Dart, JK; Hughes, R; Kilvington, S; Matheson, M; Pérez-Santonja, JJ; Tufail, A, 2003) |
| "To report patients with acanthamoeba keratitis treated with the association of propamidine (Brolene) and polyhexamethylbiguanide (PHMB) 0." | 3.71 | [Acanthamoeba keratitis treated with propamidine and polyhexamethyl biguanide (PHMB)]. ( Donoso, R; López, M; Mura, JJ, 2002) |
| "This study investigates the clinical outcome of Acanthamoeba keratitis treated with polyhexamethyl biguanide (PHMB) and propamidine isethionate (Brolene)." | 3.69 | Outcome of acanthamoeba keratitis treated with polyhexamethyl biguanide and propamidine. ( Allan, BD; Dart, JK; Duguid, IG; Ficker, L; Matheson, M; Morlet, N; Tuft, S, 1997) |
| " The rates of dose-limiting adverse events (DLAEs) leading to interruption of dosing, mild adverse events (AEs) (not dose limiting) and incidental AEs (unrelated to treatment) were compared." | 3.11 | Safety and tolerability of topical polyhexamethylene biguanide: a randomised clinical trial in healthy adult volunteers. ( Asero, N; Dart, JKG; Minassian, DC; Overweel, J; Papa, V; Rottey, S; Sallet, G; van der Meulen, I, 2022) |
| "After 4 months of the treatment, dacryoadenitis and keratitis regressed." | 2.55 | Dacryoadenitis and extraocular muscle inflammation associated with contact lens-related Acanthamoeba keratitis: A case report and review of the literature. ( Altun, A; Aydın Kurna, S; Irkec, M; Kökcen, K; Sengor, T; Yalcin, NG; Yuzbasioglu, E, 2017) |
| "Acanthamoeba keratitis is a corneal disease associated predominantly with contact lens wear." | 2.42 | [Treatment of Acanthamoeba keratitis: possibilities, problems, and new approaches]. ( Aspöck, H; Duchêne, M; Eibl, H; Walochnik, J, 2003) |
| "Acanthamoeba keratitis is a potential threat, with 85% of the cases being reported in contact lens wearers." | 2.41 | Methods used to evaluate the effectiveness of contact lens care solutions and other compounds against Acanthamoeba: a review of the literature. ( Buck, SL; Rosenthal, RA; Schlech, BA, 2000) |
| " Cultured human corneal epithelial (HCE) cells and Acanthamoeba were treated with polyhexamethylene biguanide (PHMB) combined with cellulose synthesis inhibitors to evaluate the CPE as an antiamebic agent." | 1.42 | Potential Value of Cellulose Synthesis Inhibitors Combined With PHMB in the Treatment of Acanthamoeba Keratitis. ( Chung, DI; Goo, YK; Hong, Y; Kong, HH; Moon, EK, 2015) |
| "Acanthamoeba keratitis was diagnosed on microbiological culture in 94 eyes (48." | 1.40 | The impact of topical corticosteroid use before diagnosis on the outcome of Acanthamoeba keratitis. ( Carnt, N; Dart, JK; Minassian, DC; Robaei, D, 2014) |
| "Acanthamoeba keratitis is a rare but serious corneal disease, often observed in contact lens wearers." | 1.39 | Raman microspectroscopy analysis in the treatment of acanthamoeba keratitis. ( Capriglione, P; Cennamo, G; Cerulli, L; Del Prete, S; Di Cave, D; Pesce, G; Rusciano, G; Sasso, A, 2013) |
| "Acanthamoeba keratitis is a debilitating eye disease that requires effective topical drug therapy." | 1.39 | Development of a practical complete-kill assay to evaluate anti-Acanthamoeba drugs. ( Abdel Aziz, S; Kowalski, RP; Nau, AC; Raju, LV; Romanowski, EG; Shanks, RM, 2013) |
| "Acanthamoeba keratitis is a painful corneal infection and difficult to treat because no sufficiently efficient drug has yet been available." | 1.38 | Efficacy of miltefosine for topical treatment of Acanthamoeba keratitis in Syrian hamsters. ( Obwaller, A; Polat, ZA; Vural, A; Walochnik, J, 2012) |
| "Bilateral Acanthamoeba keratitis was diagnosed by culture using nonnutrient agar overlaid with viable Escherichia coli." | 1.36 | Bilateral acanthamoeba keratitis after orthokeratology. ( Kim, EC; Kim, MS, 2010) |
| "Bilateral Acanthamoeba keratitis was diagnosed by culture by using non-nutrient agar overlaid with viable Escherichia coli." | 1.35 | Bilateral acanthamoeba keratitis after orthokeratology. ( Kim, EC; Kim, MS, 2009) |
| "Acanthamoeba keratitis is a rare but severe corneal infection which, despite improvements in diagnosis and treatment, still culminates in prolonged morbidity and significant loss of visual acuity." | 1.34 | [Acanthamoeba keratitis: about the first two Tunisian cases]. ( Ayadi, A; Ben Salah, S; Ben Zina, Z; Cheikrouhou, F; Colin, J; Feki, J; Makni, F; Mlik, M, 2007) |
| "Acanthamoeba keratitis was not suspected initially as he was a daily disposable contact lens wearer." | 1.33 | Acanthamoeba keratitis associated with misuse of daily disposable contact lenses. ( Illingworth, CD; Niyadurupola, N, 2006) |
| "One month later recurrence appeared in the right eye, as a central corneal infiltrate in the graft." | 1.32 | Bilateral Acanthamoeba keratitis with late recurrence of the infection in a corneal graft: a case report. ( Brancato, R; Matuska, S; Paganoni, G; Rama, P; Spinelli, A; Viganò, M, 2003) |
| "Following successful treatment of Acanthamoeba keratitis, the LASIK procedure can be performed on previously infected cornea with successful results." | 1.32 | Laser in situ keratomileusis treatment for myopia after Acanthamoeba keratitis. ( Lim, L; Wei, RH, 2004) |
| "Acanthamoeba keratitis is an uncommon corneal infection that can run a protracted course with, at times, serious visual results." | 1.30 | Acanthamoeba keratitis in New Zealand, including two cases with in vivo resistance to polyhexamethylene biguanide. ( Cursons, R; Gray, TB; Murdoch, D; Parr, D, 1998) |
| "From July 1996 to March 1997, three cases of Acanthamoeba keratitis combined with fungal infection were diagnosed and treated at our ophthalmic department." | 1.30 | Treatment of Acanthamoeba keratitis combined with fungal infection with polyhexamethylene biguanide. ( Sheu, MM; Tien, SH, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 22 (20.56) | 18.2507 |
| 2000's | 40 (37.38) | 29.6817 |
| 2010's | 34 (31.78) | 24.3611 |
| 2020's | 11 (10.28) | 2.80 |
| Authors | Studies |
|---|---|
| Roszkowska, AM | 1 |
| Severo, AA | 1 |
| Biondo, C | 1 |
| Postorino, EI | 1 |
| Inferrera, L | 1 |
| Aragona, P | 1 |
| Lee, PY | 2 |
| Lin, CC | 1 |
| Chiu, LY | 1 |
| Papa, V | 2 |
| Rama, P | 2 |
| Radford, C | 1 |
| Minassian, DC | 3 |
| Dart, JKG | 2 |
| Li, W | 1 |
| Wang, Z | 1 |
| Qu, J | 1 |
| Zhang, Y | 1 |
| Sun, X | 1 |
| Bagga, B | 2 |
| Sharma, S | 3 |
| Gour, RPS | 2 |
| Mohamed, A | 2 |
| Joseph, J | 2 |
| M Rathi, V | 1 |
| Garg, P | 2 |
| Lakhani, BK | 1 |
| Thajudeen, B | 1 |
| Jawaid, I | 1 |
| Attzs, MS | 1 |
| Maharajan, VS | 1 |
| Sharma, G | 1 |
| Kalra, SK | 1 |
| Tejan, N | 1 |
| Ghoshal, U | 1 |
| Thulasi, P | 1 |
| Saeed, HN | 1 |
| Rapuano, CJ | 2 |
| Hou, JH | 1 |
| Appenheimer, AB | 1 |
| Chodosh, J | 1 |
| Kang, JJ | 1 |
| Morrill, AM | 1 |
| Vyas, N | 1 |
| Zegans, ME | 2 |
| Zuckerman, R | 1 |
| Tu, EY | 3 |
| Bonini, S | 1 |
| Di Zazzo, A | 1 |
| Varacalli, G | 1 |
| Coassin, M | 1 |
| van der Meulen, I | 1 |
| Rottey, S | 1 |
| Sallet, G | 1 |
| Overweel, J | 1 |
| Asero, N | 1 |
| Rathi, V | 1 |
| Iovieno, A | 1 |
| Yeung, SN | 1 |
| Szentmáry, N | 1 |
| Módis, L | 1 |
| Imre, L | 1 |
| Füst, Á | 1 |
| Daas, L | 1 |
| Laurik, L | 1 |
| Seitz, B | 1 |
| Nagy, ZZ | 1 |
| Dos Santos, DL | 1 |
| Kwitko, S | 1 |
| Marinho, DR | 1 |
| de Araújo, BS | 1 |
| Locatelli, CI | 1 |
| Rott, MB | 2 |
| Battaini, A | 1 |
| La Scola, B | 1 |
| Yin, GHW | 1 |
| Hoffart, L | 1 |
| Drancourt, M | 1 |
| Moon, EK | 2 |
| Choi, HS | 1 |
| Kong, HH | 6 |
| Quan, FS | 1 |
| Alfonso-Muñoz, EA | 1 |
| Roig-Revert, MJ | 1 |
| Fernández-López, E | 1 |
| Hernández-Díaz, M | 1 |
| Araujo-Miranda, R | 1 |
| Peris-Martínez, C | 1 |
| Buchele, MLC | 1 |
| Wopereis, DB | 1 |
| Casara, F | 1 |
| de Macedo, JP | 1 |
| Monteiro, FBF | 1 |
| Bazzo, ML | 1 |
| Dos Reis Spada, F | 1 |
| Dos Santos, JI | 1 |
| Caumo, KS | 1 |
| Lee, K | 1 |
| Song, HB | 1 |
| Cho, W | 1 |
| Kim, JH | 3 |
| Ryu, W | 1 |
| Hassan, F | 1 |
| Bhatti, A | 1 |
| Desai, R | 1 |
| Barua, A | 1 |
| Martín-Pérez, T | 1 |
| Lozano-Cruz, T | 1 |
| Criado-Fornelio, A | 1 |
| Ortega, P | 1 |
| Gómez, R | 1 |
| de la Mata, FJ | 1 |
| Pérez-Serrano, J | 1 |
| van Zyl, LM | 1 |
| Andrew, N | 1 |
| Chehade, M | 1 |
| Sadlon, TA | 1 |
| Badenoch, PR | 1 |
| Polat, ZA | 3 |
| Walochnik, J | 4 |
| Obwaller, A | 2 |
| Vural, A | 3 |
| Dursun, A | 1 |
| Arici, MK | 1 |
| Mafra, CS | 1 |
| Carrijo-Carvalho, LC | 1 |
| Chudzinski-Tavassi, AM | 1 |
| Taguchi, FM | 1 |
| Foronda, AS | 1 |
| Carvalho, FR | 1 |
| de Freitas, D | 1 |
| Rusciano, G | 1 |
| Capriglione, P | 1 |
| Pesce, G | 1 |
| Del Prete, S | 1 |
| Cennamo, G | 1 |
| Di Cave, D | 1 |
| Cerulli, L | 1 |
| Sasso, A | 1 |
| Kowalski, RP | 2 |
| Abdel Aziz, S | 1 |
| Romanowski, EG | 1 |
| Shanks, RM | 2 |
| Nau, AC | 1 |
| Raju, LV | 1 |
| Tran, T | 1 |
| Samarawickrama, C | 1 |
| Petsoglou, C | 1 |
| Watson, S | 1 |
| Robaei, D | 1 |
| Carnt, N | 1 |
| Dart, JK | 7 |
| Bouheraoua, N | 2 |
| Labbé, A | 1 |
| Chaumeil, C | 3 |
| Liang, Q | 1 |
| Laroche, L | 3 |
| Borderie, V | 2 |
| Alkharashi, M | 1 |
| Lindsley, K | 1 |
| Law, HA | 1 |
| Sikder, S | 1 |
| Kolar, SS | 1 |
| Manarang, JC | 1 |
| Burns, AR | 1 |
| Miller, WL | 1 |
| McDermott, AM | 1 |
| Bergmanson, JP | 1 |
| Hong, Y | 1 |
| Chung, DI | 5 |
| Goo, YK | 1 |
| Reichart-Peter, S | 1 |
| Manousaridis, K | 1 |
| Dirschmid, H | 1 |
| Mennel, S | 1 |
| Siddiqui, R | 1 |
| Aqeel, Y | 1 |
| Khan, NA | 1 |
| Kwok, PW | 1 |
| Kam, KW | 1 |
| Jhanji, V | 1 |
| Young, AL | 1 |
| Sengor, T | 1 |
| Yuzbasioglu, E | 1 |
| Aydın Kurna, S | 1 |
| Irkec, M | 1 |
| Altun, A | 1 |
| Kökcen, K | 1 |
| Yalcin, NG | 1 |
| Lin, HC | 1 |
| Hsiao, CH | 1 |
| Ma, DH | 1 |
| Yeh, LK | 1 |
| Tan, HY | 1 |
| Lin, MY | 1 |
| Huang, SC | 1 |
| Joslin, CE | 1 |
| Sugar, J | 1 |
| Shoff, ME | 1 |
| Booton, GC | 1 |
| Thompson, PP | 1 |
| Gordon, YJ | 1 |
| Sahu, SK | 1 |
| Das, S | 1 |
| Vemuganti, GK | 1 |
| Xuan, YH | 3 |
| Chung, BS | 1 |
| Hong, YC | 1 |
| Hahn, TW | 3 |
| Kim, EC | 2 |
| Kim, MS | 2 |
| McKelvie, J | 1 |
| Patel, D | 1 |
| McGhee, C | 1 |
| Saw, VP | 1 |
| Kilvington, S | 4 |
| Guerriero, S | 1 |
| La Tegola, MG | 1 |
| Monno, R | 1 |
| Apruzzese, M | 1 |
| Cantatore, A | 1 |
| Guyomarch, J | 1 |
| van Nuoï, DN | 1 |
| Beral, L | 1 |
| Donnio, A | 1 |
| Desbois, N | 1 |
| Olive, C | 1 |
| Theodose, R | 1 |
| Merle, H | 1 |
| Khan, YA | 1 |
| Kashiwabuchi, RT | 1 |
| Martins, SA | 1 |
| Castro-Combs, JM | 1 |
| Kalyani, S | 1 |
| Stanley, P | 1 |
| Flikier, D | 1 |
| Behrens, A | 1 |
| Ohashi, Y | 1 |
| Sasaki, M | 1 |
| Sotozono, C | 1 |
| Chihara, H | 1 |
| Ueta, M | 1 |
| Inatomi, T | 1 |
| Yokoi, N | 1 |
| Shiota, T | 1 |
| Kinoshita, S | 1 |
| Oldenburg, CE | 1 |
| Acharya, NR | 1 |
| Mannis, MJ | 1 |
| Gaynor, BD | 1 |
| Whitcher, JP | 1 |
| Lietman, TM | 1 |
| Keenan, JD | 1 |
| Arnalich-Montiel, F | 1 |
| Lorenzo-Morales, J | 1 |
| Irigoyen, C | 1 |
| Morcillo-Laiz, R | 1 |
| López-Vélez, R | 1 |
| Muñoz-Negrete, F | 1 |
| Piñero, JE | 1 |
| Valladares, B | 1 |
| Gaujoux, T | 1 |
| Goldschmidt, P | 1 |
| Borderie, VM | 1 |
| Cremona, G | 1 |
| Carrasco, MA | 1 |
| Tytiun, A | 1 |
| Cosentino, MJ | 1 |
| Matuska, S | 1 |
| Viganò, M | 1 |
| Spinelli, A | 1 |
| Paganoni, G | 1 |
| Brancato, R | 1 |
| Pérez-Santonja, JJ | 1 |
| Hughes, R | 1 |
| Tufail, A | 1 |
| Matheson, M | 3 |
| Khunkitti, W | 1 |
| Hann, AC | 1 |
| Lloyd, D | 1 |
| Furr, JR | 1 |
| Russell, AD | 1 |
| Lim, L | 1 |
| Wei, RH | 1 |
| Seal, D | 1 |
| Duchêne, M | 1 |
| Eibl, H | 1 |
| Aspöck, H | 1 |
| Bourcier, T | 1 |
| Patteau, F | 1 |
| Baudrimont, M | 1 |
| Rondeau, N | 1 |
| Bonnel, S | 1 |
| Mathers, W | 1 |
| Vasseneix, C | 1 |
| Gargala, G | 1 |
| François, A | 1 |
| Hellot, MF | 1 |
| Duclos, C | 1 |
| Muraine, M | 1 |
| Benichou, J | 1 |
| Ballet, JJ | 1 |
| Brasseur, G | 1 |
| Favennec, L | 1 |
| Georgakopoulos, CD | 1 |
| Exarchou, AM | 1 |
| Gartaganis, SP | 1 |
| Niyadurupola, N | 1 |
| Illingworth, CD | 1 |
| Ertabaklar, H | 1 |
| Türk, M | 1 |
| Dayanir, V | 1 |
| Ertuğ, S | 1 |
| Lee, SJ | 2 |
| Jeong, HJ | 2 |
| Lee, JE | 3 |
| Lee, JS | 3 |
| Ock, MS | 2 |
| Yu, HS | 4 |
| Stemberger, K | 1 |
| Dick, B | 1 |
| Kramann, C | 1 |
| Thieme, H | 1 |
| Weber, A | 1 |
| Petry, F | 1 |
| Pfeiffer, N | 1 |
| Oum, BS | 1 |
| Choi, HY | 1 |
| Ben Salah, S | 1 |
| Makni, F | 1 |
| Cheikrouhou, F | 1 |
| Ben Zina, Z | 1 |
| Mlik, M | 1 |
| Feki, J | 1 |
| Colin, J | 1 |
| Ayadi, A | 1 |
| Cetin, A | 1 |
| Lee, KH | 1 |
| Park, SK | 1 |
| Choi, SH | 2 |
| Thebpatiphat, N | 1 |
| Hammersmith, KM | 1 |
| Rocha, FN | 1 |
| Ayres, BD | 1 |
| Laibson, PR | 1 |
| Eagle, RC | 1 |
| Cohen, EJ | 1 |
| Pineda, R | 1 |
| Kocatürk, T | 1 |
| Bhui, RD | 1 |
| Wong, VW | 1 |
| Chi, SC | 1 |
| Lam, DS | 2 |
| Lim, N | 1 |
| Goh, D | 1 |
| Bunce, C | 1 |
| Xing, W | 1 |
| Fraenkel, G | 1 |
| Poole, TR | 1 |
| Ficker, L | 2 |
| Herz, NL | 1 |
| Matoba, AY | 1 |
| Wilhelmus, KR | 2 |
| Winchester, K | 1 |
| Mathers, WD | 1 |
| Sutphin, JE | 1 |
| Daley, TE | 1 |
| Ruddell, TJ | 1 |
| Easty, DL | 1 |
| Seal, DV | 2 |
| Hay, J | 2 |
| Kirkness, CM | 1 |
| Elder, MJ | 1 |
| Gray, TB | 2 |
| Gross, KA | 1 |
| Cursons, RT | 1 |
| Shewan, JF | 1 |
| Bacon, AS | 1 |
| Frazer, DG | 1 |
| Ficker, LA | 1 |
| Wright, P | 1 |
| Yee, E | 1 |
| Fiscella, R | 1 |
| Winarko, TK | 1 |
| Mills, RA | 1 |
| Osato, MS | 1 |
| Pyron, M | 1 |
| Varga, JH | 1 |
| Wolf, TC | 1 |
| Jensen, HG | 1 |
| Parmley, VC | 1 |
| Rowsey, JJ | 1 |
| Pfister, DR | 1 |
| Cameron, JD | 1 |
| Krachmer, JH | 1 |
| Holland, EJ | 1 |
| Eggink, CA | 1 |
| Vaandrager, W | 1 |
| Burger, DM | 1 |
| Sauerwein, RW | 1 |
| Kumar, B | 1 |
| Crawford, GJ | 1 |
| Duguid, IG | 1 |
| Morlet, N | 1 |
| Allan, BD | 1 |
| Tuft, S | 1 |
| Sullivan, L | 1 |
| Tseng, SH | 1 |
| Lin, SC | 1 |
| Chen, FK | 1 |
| Murdoch, D | 1 |
| Cursons, R | 1 |
| Parr, D | 1 |
| Tien, SH | 1 |
| Sheu, MM | 1 |
| Buck, SL | 1 |
| Rosenthal, RA | 1 |
| Schlech, BA | 1 |
| Wysenbeek, YS | 1 |
| Blank-Porat, D | 1 |
| Harizman, N | 1 |
| Wygnanski-Jaffe, T | 1 |
| Keller, N | 1 |
| Avni, I | 1 |
| Panda, A | 1 |
| Das, GK | 1 |
| Biswas, NR | 1 |
| Mittal, D | 1 |
| Mohanty, S | 1 |
| Lyon, D | 1 |
| Poon, AS | 1 |
| Rao, SK | 1 |
| Fan, DS | 1 |
| Gajdatsy, AD | 1 |
| Kosmin, A | 1 |
| Barrett, GD | 1 |
| Narasimhan, S | 1 |
| Madhavan, HN | 1 |
| K, LT | 1 |
| Donoso, R | 1 |
| Mura, JJ | 1 |
| López, M | 1 |
| Larkin, DF | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized, Active-Controlled, Phase 3 Study to Evaluate Efficacy, Safety and Tolerability of 0.08% PHMB Ophthalmic Solution in Comparison With 0.02% PHMB + 0.1% Propamidine Combination Therapy in Subjects Affected by Acanthamoeba Keratitis[NCT03274895] | Phase 3 | 135 participants (Actual) | Interventional | 2017-08-13 | Completed | ||
| Randomized, Double-Masked, Placebo-Controlled Multiple-Dose Phase 1 Study to Evaluate the Safety and Tolerability of Different Doses of Preservative-free Polyhexamethylene Biguanide (PHMB) Ophthalmic Solution in Healthy Subjects[NCT02506257] | Phase 1 | 90 participants (Actual) | Interventional | 2015-11-30 | Completed | ||
| Retrospective Study of the in Vivo Confocal Microscopic Findings and the Treatment Outcome of Acanthamoebic Keratitis[NCT02763605] | 100 participants (Anticipated) | Observational | 2014-01-31 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Percentage of patients cured 30 days after discontinuing all study therapies, within 12 months of randomization (NCT03274895)
Timeframe: 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| PHMB 0.08% Plus Placebo | 84.8 |
| PHMB 0.02% Plus Propamidine 0.1% | 88.5 |
Time needed to reach a clinical resolution (NCT03274895)
Timeframe: maximum 12 months
| Intervention | days (Median) |
|---|---|
| PHMB 0.08% Plus Placebo | 140 |
| PHMB 0.02% Plus Propamidine 0.1% | 114 |
Final visual acuity (best corrected) (NCT03274895)
Timeframe: maximum 12 months
| Intervention | LogMAR (Median) |
|---|---|
| PHMB 0.08% Plus Placebo | 0.000 |
| PHMB 0.02% Plus Propamidine 0.1% | 0.000 |
Change from baseline conjunctival staining at Day 14. Staining with lissamine green was used. The density of staining was graded with the Oxford Score. Score range was between 0-15. An increase in the score after treatment represent a negative outcome (NCT02506257)
Timeframe: Baseline and Day 14
| Intervention | scores on a scale (Mean) |
|---|---|
| 0.04% PHMB | 0.7 |
| 0.06% PHMB | 1.2 |
| 0.08% PHMB | 1.7 |
| PHMB Vehicle | 1.0 |
(NCT02506257)
Timeframe: up to 21 days from date of randomization
| Intervention | participants (Number) |
|---|---|
| 0.04% PHMB | 0 |
| 0.06% PHMB | 2 |
| 0.08% PHMB | 3 |
| PHMB Vehicle | 0 |
Change from baseline OSDI at D 14. Score range was betwwen 0-100. An increase of OSDI values with treatment represent a negative outcome. (NCT02506257)
Timeframe: Baseline and Day 14
| Intervention | scores on a scale (Mean) |
|---|---|
| 0.04% PHMB | 1.5 |
| 0.06% PHMB | 1.3 |
| 0.08% PHMB | 4.2 |
| PHMB Vehicle | -2.2 |
(NCT02506257)
Timeframe: Day14
| Intervention | micrograms/ml (Mean) |
|---|---|
| 0.04% PHMB | 0 |
| 0.06% PHMB | 0 |
| 0.08% PHMB | 0 |
| PHMB Vehicle | 0 |
Change from baseline systolic blood pressure (NCT02506257)
Timeframe: Baseline and Day 14
| Intervention | mmHg (Mean) |
|---|---|
| 0.04% PHMB | -0.7 |
| 0.06% PHMB | 0.6 |
| 0.08% PHMB | -0.9 |
| PHMB Vehicle | 1.0 |
Change from baseline Visual acuity. Best corrected visual acuity was reported in decimal fraction. A decrease of visual acuity during treatment was considered a negative safety outcome. (NCT02506257)
Timeframe: Baseline and Day 14
| Intervention | decimals (Mean) |
|---|---|
| 0.04% PHMB | 0.3 |
| 0.06% PHMB | 0.3 |
| 0.08% PHMB | 0.3 |
| PHMB Vehicle | 0.3 |
12 reviews available for biguanides and Keratitis, Acanthamoeba
| Article | Year |
|---|---|
Combined Phialemonium curvatum and Acanthamoeba Keratitis: The Importance of Early Diagnosis and Specific Therapy.
Topics: Acanthamoeba Keratitis; Administration, Ophthalmic; Anti-Bacterial Agents; Antifungal Agents; Ascomy | 2021 |
Nanoparticles based therapeutic efficacy against Acanthamoeba: Updates and future prospect.
Topics: Acanthamoeba; Acanthamoeba Keratitis; Amebiasis; Amebicides; Biguanides; Central Nervous System Prot | 2020 |
[Diagnostics and treatment of infectious keratitis].
Topics: Acanthamoeba Keratitis; Adrenal Cortex Hormones; Anti-Bacterial Agents; Antiprotozoal Agents; Biguan | 2017 |
[Acanthamoeba keratitis].
Topics: Acanthamoeba; Acanthamoeba Keratitis; Adrenal Cortex Hormones; Amebicides; Animals; Biguanides; Cata | 2014 |
Medical interventions for acanthamoeba keratitis.
Topics: Acanthamoeba Keratitis; Anti-Infective Agents, Local; Biguanides; Chlorhexidine; Humans; Randomized | 2015 |
The Development of Drugs against Acanthamoeba Infections.
Topics: Acanthamoeba; Acanthamoeba Keratitis; Amphotericin B; Animals; Antiprotozoal Agents; Azoles; Biguani | 2016 |
Dacryoadenitis and extraocular muscle inflammation associated with contact lens-related Acanthamoeba keratitis: A case report and review of the literature.
Topics: Acanthamoeba Keratitis; Adult; Anti-Bacterial Agents; Antiprotozoal Agents; Benzamidines; Biguanides | 2017 |
Acanthamoeba keratitis presenting as a plaque.
Topics: Acanthamoeba Keratitis; Atropine; Biguanides; Ciprofloxacin; Cornea; Diagnosis, Differential; Drug A | 2008 |
Acanthamoeba keratitis: diagnosis and treatment update 2009.
Topics: Acanthamoeba; Acanthamoeba Keratitis; Animals; Biguanides; Contact Lenses; Cryotherapy; Early Diagno | 2009 |
Treatment of Acanthamoeba keratitis.
Topics: Acanthamoeba Keratitis; Amebicides; Anti-Bacterial Agents; Anti-Infective Agents, Local; Antiprotozo | 2003 |
[Treatment of Acanthamoeba keratitis: possibilities, problems, and new approaches].
Topics: Acanthamoeba Keratitis; Antiprotozoal Agents; Benzamidines; Biguanides; Contact Lens Solutions; Cont | 2003 |
Methods used to evaluate the effectiveness of contact lens care solutions and other compounds against Acanthamoeba: a review of the literature.
Topics: Acanthamoeba; Acanthamoeba Keratitis; Animals; Anti-Infective Agents, Local; Biguanides; Chlorhexidi | 2000 |
3 trials available for biguanides and Keratitis, Acanthamoeba
| Article | Year |
|---|---|
A randomized masked pilot clinical trial to compare the efficacy of topical 1% voriconazole ophthalmic solution as monotherapy with combination therapy of topical 0.02% polyhexamethylene biguanide and 0.02% chlorhexidine in the treatment of Acanthamoeba k
Topics: Acanthamoeba Keratitis; Biguanides; Chlorhexidine; Humans; Ophthalmic Solutions; Prospective Studies | 2021 |
Safety and tolerability of topical polyhexamethylene biguanide: a randomised clinical trial in healthy adult volunteers.
Topics: Acanthamoeba Keratitis; Adult; Biguanides; Healthy Volunteers; Humans; Prospective Studies | 2022 |
Safety and tolerability of topical polyhexamethylene biguanide: a randomised clinical trial in healthy adult volunteers.
Topics: Acanthamoeba Keratitis; Adult; Biguanides; Healthy Volunteers; Humans; Prospective Studies | 2022 |
Safety and tolerability of topical polyhexamethylene biguanide: a randomised clinical trial in healthy adult volunteers.
Topics: Acanthamoeba Keratitis; Adult; Biguanides; Healthy Volunteers; Humans; Prospective Studies | 2022 |
Safety and tolerability of topical polyhexamethylene biguanide: a randomised clinical trial in healthy adult volunteers.
Topics: Acanthamoeba Keratitis; Adult; Biguanides; Healthy Volunteers; Humans; Prospective Studies | 2022 |
Comparison of polyhexamethylene biguanide and chlorhexidine as monotherapy agents in the treatment of Acanthamoeba keratitis.
Topics: Acanthamoeba Keratitis; Adult; Biguanides; Chlorhexidine; Disinfectants; Double-Blind Method; Female | 2008 |
92 other studies available for biguanides and Keratitis, Acanthamoeba
| Article | Year |
|---|---|
Bilateral radial keratoneuritis resulting from acanthamoeba keratitis.
Topics: Acanthamoeba; Acanthamoeba Keratitis; Adolescent; Anti-Infective Agents, Local; Biguanides; Chlorhex | 2022 |
Topics: Acanthamoeba Keratitis; Adolescent; Adult; Aged; Antiprotozoal Agents; Biguanides; Chlorhexidine; Di | 2020 |
Acanthamoeba keratitis related to contact lens use in a tertiary hospital in China.
Topics: Acanthamoeba; Acanthamoeba Keratitis; Adolescent; Adult; Anti-Infective Agents, Local; Biguanides; C | 2019 |
Endotheliitis-A Presentation of Acanthamoeba Keratitis.
Topics: Acanthamoeba Keratitis; Administration, Ophthalmic; Adult; Antiprotozoal Agents; Benzamidines; Bigua | 2021 |
Oral Miltefosine as Salvage Therapy for Refractory Acanthamoeba Keratitis.
Topics: Acanthamoeba Keratitis; Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antiprotoz | 2021 |
Acanthamoeba Keratitis: Perspectives for Patients.
Topics: Acanthamoeba Keratitis; Adolescent; Adult; Aged; Antiprotozoal Agents; Benzamidines; Biguanides; Chi | 2021 |
Response to 'Comment on: 'A randomized masked pilot clinical trial to compare the efficacy of topical 1% Voriconazole ophthalmic solution as monotherapy to combination therapy with topical 0.02% Polyhexamethylene biguanide and 0.02% Chlorhexidine in the t
Topics: Acanthamoeba Keratitis; Biguanides; Chlorhexidine; Humans; Ophthalmic Solutions; Voriconazole | 2022 |
Comment on: 'A randomized masked pilot clinical trial to compare the efficacy of topical 1% voriconazole ophthalmic solution as monotherapy with combination therapy of topical 0.02% polyhexamethylene biguanide and 0.02% chlorhexidine in the treatment of A
Topics: Acanthamoeba Keratitis; Biguanides; Chlorhexidine; Humans; Ophthalmic Solutions; Voriconazole | 2022 |
Acanthamoeba keratitis in Porto Alegre (southern Brazil): 28 cases and risk factors.
Topics: Acanthamoeba Keratitis; Adult; Benzamidines; Biguanides; Brazil; Chlorhexidine; Contact Lens Solutio | 2018 |
Amebaborne "Attilina massiliensis" Keratitis, France.
Topics: Acanthamoeba castellanii; Acanthamoeba Keratitis; Adolescent; Alphaproteobacteria; Benzamidines; Big | 2018 |
Polyhexamethylene biguanide and chloroquine induce programmed cell death in Acanthamoeba castellanii.
Topics: Acanthamoeba castellanii; Acanthamoeba Keratitis; Amebicides; Biguanides; Cell Nucleus; Cells, Cultu | 2018 |
A report of 10 patients with Acanthamoeba keratitis.
Topics: Acanthamoeba Keratitis; Adolescent; Amebicides; Biguanides; Child; Conjunctivitis; Contact Lenses; C | 2018 |
Contact lens-related polymicrobial keratitis: Acanthamoeba spp. genotype T4 and Candida albicans.
Topics: Acanthamoeba; Acanthamoeba Keratitis; Adult; Biguanides; Candida albicans; Candidiasis; Chlorhexidin | 2018 |
Intracorneal injection of a detachable hybrid microneedle for sustained drug delivery.
Topics: Acanthamoeba Keratitis; Animals; Biguanides; Cornea; Dimethylpolysiloxanes; Drug Delivery Systems; F | 2018 |
Analysis from a year of increased cases of Acanthamoeba Keratitis in a large teaching hospital in the UK.
Topics: Acanthamoeba; Acanthamoeba Keratitis; Adult; Anti-Infective Agents, Local; Antiprotozoal Agents; Ben | 2019 |
Synthesis and in vitro activity of new biguanide-containing dendrimers on pathogenic isolates of Acanthamoeba polyphaga and Acanthamoeba griffini.
Topics: Acanthamoeba; Acanthamoeba Keratitis; Amebicides; Animals; Biguanides; Cell Line, Tumor; Chlorhexidi | 2019 |
Acanthamoeba lenticulata keratitis in a hard contact lens wearer.
Topics: Acanthamoeba; Acanthamoeba Keratitis; Adult; Antiprotozoal Agents; Benzamidines; Biguanides; Contact | 2013 |
Miltefosine and polyhexamethylene biguanide: a new drug combination for the treatment of Acanthamoeba keratitis.
Topics: Acanthamoeba; Acanthamoeba Keratitis; Animals; Antiprotozoal Agents; Biguanides; Cell Line; Cell Pro | 2014 |
Antimicrobial action of biguanides on the viability of Acanthamoeba cysts and assessment of cell toxicity.
Topics: Acanthamoeba castellanii; Acanthamoeba Keratitis; Animals; Biguanides; Cell Survival; Cornea; Cysts; | 2013 |
Raman microspectroscopy analysis in the treatment of acanthamoeba keratitis.
Topics: Acanthamoeba; Acanthamoeba Keratitis; Amebicides; Biguanides; Contact Lenses; Cytoplasm; Humans; Mod | 2013 |
Development of a practical complete-kill assay to evaluate anti-Acanthamoeba drugs.
Topics: Acanthamoeba; Acanthamoeba Keratitis; Antiprotozoal Agents; Benzamidines; Biguanides; Chlorhexidine; | 2013 |
Recent cluster of childhood microbial keratitis due to orthokeratology.
Topics: Acanthamoeba Keratitis; Adolescent; Anti-Bacterial Agents; Biguanides; Cephalothin; Child; Chlorhexi | 2014 |
The impact of topical corticosteroid use before diagnosis on the outcome of Acanthamoeba keratitis.
Topics: Acanthamoeba Keratitis; Administration, Topical; Adolescent; Adult; Antiprotozoal Agents; Biguanides | 2014 |
Contact lens care solution killing efficacy against Acanthamoeba castellanii by in vitro testing and live-imaging.
Topics: Acanthamoeba castellanii; Acanthamoeba Keratitis; Amebiasis; Amebicides; Animals; Biguanides; Contac | 2015 |
Potential Value of Cellulose Synthesis Inhibitors Combined With PHMB in the Treatment of Acanthamoeba Keratitis.
Topics: Acanthamoeba castellanii; Acanthamoeba Keratitis; Amebicides; Animals; Benzamides; Biguanides; Cells | 2015 |
[Good outcome in Acanthamoeba keratitis].
Topics: Acanthamoeba Keratitis; Adult; Antiprotozoal Agents; Benzamidines; Biguanides; Dose-Response Relatio | 2017 |
Painless Acanthamoeba Keratitis with Normal Vision.
Topics: Acanthamoeba; Acanthamoeba Keratitis; Adolescent; Antiprotozoal Agents; Benzamidines; Biguanides; Co | 2017 |
Medical treatment for combined Fusarium and Acanthamoeba keratitis.
Topics: Acanthamoeba Keratitis; Administration, Topical; Adolescent; Adult; Aged; Antifungal Agents; Antipro | 2009 |
Prognostic factors affecting visual outcome in Acanthamoeba keratitis.
Topics: Acanthamoeba Keratitis; Adult; Antiprotozoal Agents; Benzamidines; Biguanides; Case-Control Studies; | 2008 |
Validation of real-time PCR for laboratory diagnosis of Acanthamoeba keratitis.
Topics: Acanthamoeba; Acanthamoeba Keratitis; Animals; Biguanides; DNA Primers; Enzyme Inhibitors; Humans; P | 2008 |
Keratitis by Acanthamoeba triangularis: report of cases and characterization of isolates.
Topics: Acanthamoeba; Acanthamoeba Keratitis; Adolescent; Adult; Animals; Antiprotozoal Agents; Biguanides; | 2008 |
Bilateral acanthamoeba keratitis after orthokeratology.
Topics: Acanthamoeba Keratitis; Biguanides; Contact Lenses, Extended-Wear; Drug Therapy, Combination; Female | 2009 |
Cosmetic contact lens-related Acanthamoeba keratitis.
Topics: Acanthamoeba Keratitis; Benzamidines; Biguanides; Contact Lenses; Cosmetic Techniques; Disinfectants | 2009 |
A case of descemet's membrane rupture in a patient affected by Acanthamoeba Keratitis.
Topics: Acanthamoeba Keratitis; Adult; Amebiasis; Antiprotozoal Agents; Benzamidines; Biguanides; Corneal Di | 2009 |
Bilateral acanthamoeba keratitis after orthokeratology.
Topics: Acanthamoeba Keratitis; Antiprotozoal Agents; Biguanides; Drug Therapy, Combination; Escherichia col | 2010 |
[Infectious keratitis and cosmetic lenses: a five-case retrospective study].
Topics: Abscess; Acanthamoeba Keratitis; Adolescent; Adult; Anti-Bacterial Agents; Anti-Infective Agents; An | 2010 |
Riboflavin and ultraviolet light a therapy as an adjuvant treatment for medically refractive Acanthamoeba keratitis: report of 3 cases.
Topics: Acanthamoeba Keratitis; Adult; Antiprotozoal Agents; Benzamidines; Biguanides; Chemotherapy, Adjuvan | 2011 |
[Trailing the footpath of Acanthamoeba keratitis].
Topics: Acanthamoeba Keratitis; Biguanides; Chlorhexidine; Contact Lens Solutions; Contact Lenses, Hydrophil | 2010 |
[Characteristic appearance of early-stage Acanthamoeba keratitis].
Topics: Acanthamoeba; Acanthamoeba Keratitis; Adolescent; Adrenal Cortex Hormones; Adult; Biguanides; Cornea | 2010 |
Efficacy of miltefosine for topical treatment of Acanthamoeba keratitis in Syrian hamsters.
Topics: Acanthamoeba; Acanthamoeba Keratitis; Administration, Topical; Animals; Antiprotozoal Agents; Benzam | 2012 |
Practice patterns and opinions in the treatment of acanthamoeba keratitis.
Topics: Acanthamoeba Keratitis; Adrenal Cortex Hormones; Anti-Bacterial Agents; Antiprotozoal Agents; Biguan | 2011 |
Co-isolation of Vahlkampfia and acanthamoeba in acanthamoeba-like keratitis in a Spanish population.
Topics: Acanthamoeba; Acanthamoeba Keratitis; Adult; Antifungal Agents; Antiprotozoal Agents; Benzamidines; | 2013 |
Prognostic factors associated with the need for surgical treatments in acanthamoeba keratitis.
Topics: Acanthamoeba; Acanthamoeba Keratitis; Administration, Topical; Adolescent; Adult; Aged; Aged, 80 and | 2013 |
Treatment of advanced acanthamoeba keratitis with deep lamellar keratectomy and conjunctival flap.
Topics: Acanthamoeba Keratitis; Adult; Antiprotozoal Agents; Biguanides; Conjunctiva; Contact Lenses; Cornea | 2002 |
Bilateral Acanthamoeba keratitis with late recurrence of the infection in a corneal graft: a case report.
Topics: Acanthamoeba; Acanthamoeba Keratitis; Adult; Animals; Anti-Bacterial Agents; Benzamidines; Biguanide | 2003 |
Persistently culture positive acanthamoeba keratitis: in vivo resistance and in vitro sensitivity.
Topics: Acanthamoeba; Acanthamoeba Keratitis; Adult; Amebicides; Animals; Benzamidines; Biguanides; Chlorhex | 2003 |
Biguanide-induced changes in Acanthamoeba castellanii: an electron microscopic study.
Topics: Acanthamoeba; Acanthamoeba Keratitis; Animals; Biguanides; Cell Membrane; Chlorhexidine; Cytoplasm; | 1998 |
Laser in situ keratomileusis treatment for myopia after Acanthamoeba keratitis.
Topics: Acanthamoeba Keratitis; Adult; Amebicides; Benzamidines; Biguanides; Contact Lenses, Hydrophilic; Co | 2004 |
[Amniotic membrane transplantation for the treatment severe acanthamoeba keratitis].
Topics: Acanthamoeba Keratitis; Adult; Amnion; Biguanides; Biological Dressings; Drug Therapy, Combination; | 2004 |
Use of higher medication concentrations in the treatment of acanthamoeba keratitis.
Topics: Acanthamoeba Keratitis; Anti-Infective Agents, Local; Biguanides; Chlorhexidine; Humans | 2006 |
A keratitis rat model for evaluation of anti-Acanthamoeba polyphaga agents.
Topics: Acanthamoeba; Acanthamoeba Keratitis; Administration, Topical; Animals; Antiprotozoal Agents; Benzam | 2006 |
Unusual case of acanthamoeba keratitis in a contact lens wearer.
Topics: Acanthamoeba; Acanthamoeba Keratitis; Adult; Animals; Antiparasitic Agents; Biguanides; Biopsy; Cont | 2006 |
Acanthamoeba keratitis associated with misuse of daily disposable contact lenses.
Topics: Acanthamoeba; Acanthamoeba Keratitis; Aged; Amebicides; Animals; Benzamidines; Biguanides; Contact L | 2006 |
Acanthamoeba keratitis due to Acanthamoeba genotype T4 in a non-contact-lens wearer in Turkey.
Topics: Acanthamoeba; Acanthamoeba Keratitis; Adult; Animals; Anti-Bacterial Agents; Antifungal Agents; Anti | 2007 |
Molecular characterization of Acanthamoeba isolated from amebic keratitis related to orthokeratology lens overnight wear.
Topics: Acanthamoeba; Acanthamoeba Keratitis; Adolescent; Animals; Antiprotozoal Agents; Astigmatism; Biguan | 2006 |
[Painless acanthamoeba keratitis].
Topics: Acanthamoeba Keratitis; Adult; Antiprotozoal Agents; Benzamidines; Biguanides; Combined Modality The | 2007 |
Acanthamoeba keratitis related to orthokeratology.
Topics: Acanthamoeba Keratitis; Adolescent; Anti-Infective Agents, Local; Biguanides; Chlorhexidine; Circadi | 2007 |
[Acanthamoeba keratitis: about the first two Tunisian cases].
Topics: Acanthamoeba; Acanthamoeba Keratitis; Adult; Amebicides; Animals; Antifungal Agents; Benzamidines; B | 2007 |
Efficacy of contact lens storage solutions against trophozoite and cyst of Acanthamoeba castellanii strain 1BU and their cytotoxic potential on corneal cells.
Topics: Acanthamoeba castellanii; Acanthamoeba Keratitis; Animals; Biguanides; Cell Survival; Cells, Culture | 2007 |
Acanthamoeba: keratopathogenicity of isolates from domestic tap water in Korea.
Topics: Acanthamoeba; Acanthamoeba Keratitis; Animals; Biguanides; Cell Line; Chlorhexidine; Contact Lenses; | 2007 |
Acanthamoeba keratitis: a parasite on the rise.
Topics: Acanthamoeba; Acanthamoeba Keratitis; Adolescent; Adult; Aged; Animals; Anti-Infective Agents, Local | 2007 |
Visual outcome and rehabilitation in a case of bilateral acanthamoeba sclerokeratitis.
Topics: Acanthamoeba Keratitis; Adult; Benzamidines; Biguanides; Cataract Extraction; Chloramphenicol; Drug | 2007 |
Good visual outcome after prompt treatment of acanthamoeba keratitis associated with overnight orthokeratology lens wear.
Topics: Acanthamoeba Keratitis; Benzamidines; Biguanides; Child; Circadian Rhythm; Contact Lens Solutions; C | 2007 |
Acanthamoeba keratitis related to cosmetic contact lenses.
Topics: Acanthamoeba Keratitis; Adolescent; Antiprotozoal Agents; Biguanides; Chlorhexidine; Contact Lenses; | 2007 |
Rapidly progressive cataract and iris atrophy during treatment of Acanthamoeba keratitis.
Topics: Acanthamoeba Keratitis; Administration, Topical; Adult; Aged; Antiprotozoal Agents; Atrophy; Benzami | 2008 |
Diagnosis of Acanthamoeba keratitis in vivo with confocal microscopy.
Topics: Acanthamoeba; Acanthamoeba Keratitis; Adolescent; Adult; Aged; Amebicides; Animals; Benzamidines; Bi | 1995 |
Drug therapy in a murine model of Acanthamoeba keratitis.
Topics: Acanthamoeba Keratitis; Animals; Antiprotozoal Agents; Benzamidines; Biguanides; Disease Models, Ani | 1995 |
Chlorhexidine or polyhexamethylene biguanide for acanthamoeba keratitis.
Topics: Acanthamoeba Keratitis; Biguanides; Chlorhexidine; Disinfectants; Humans; Ophthalmic Solutions | 1995 |
Chemotherapy for acanthamoeba keratitis.
Topics: Acanthamoeba Keratitis; Administration, Topical; Amebicides; Benzamidines; Biguanides; Chlorhexidine | 1995 |
Chemotherapy for acanthamoeba keratitis.
Topics: Acanthamoeba Keratitis; Antiprotozoal Agents; Benzamidines; Biguanides; Chlorhexidine; Disinfectants | 1995 |
Acanthamoeba keratitis: a sobering case and a promising new treatment.
Topics: Acanthamoeba Keratitis; Adult; Animals; Anti-Bacterial Agents; Biguanides; Cataract; Contact Lenses, | 1994 |
A review of 72 consecutive cases of Acanthamoeba keratitis, 1984-1992.
Topics: Acanthamoeba; Acanthamoeba Keratitis; Animals; Antiprotozoal Agents; Benzamidines; Biguanides; Conta | 1993 |
Topical polyhexamethylene biguanide (pool cleaner) for treatment of acanthamoeba keratitis.
Topics: Acanthamoeba Keratitis; Biguanides; Disinfectants; Humans; Ophthalmic Solutions | 1993 |
Polyhexamethylene biguanide in the treatment of Acanthamoeba keratitis.
Topics: Acanthamoeba Keratitis; Adolescent; Antiprotozoal Agents; Biguanides; Contact Lenses, Hydrophilic; D | 1993 |
Combined treatment of Acanthamoeba keratitis with propamidine, neomycin, and polyhexamethylene biguanide.
Topics: Acanthamoeba Keratitis; Adolescent; Adult; Animals; Benzamidines; Biguanides; Drug Administration Sc | 1993 |
Confocal microscopy findings of Acanthamoeba keratitis.
Topics: Acanthamoeba; Acanthamoeba Keratitis; Adolescent; Animals; Anti-Bacterial Agents; Biguanides; Contac | 1996 |
[Acanthamoeba keratitis].
Topics: Acanthamoeba Keratitis; Adult; Aged; Amebicides; Anti-Bacterial Agents; Benzamidines; Biguanides; Co | 1996 |
Acanthamoeba keratitis: risk factors and outcome.
Topics: Acanthamoeba Keratitis; Antiprotozoal Agents; Benzamidines; Biguanides; Humans | 1996 |
Should we be using polyhexamethylene biguanide to treat Acanthamoeba keratitis?
Topics: Acanthamoeba Keratitis; Administration, Topical; Biguanides; Contact Lenses; Cornea; Disinfectants; | 1997 |
Outcome of acanthamoeba keratitis treated with polyhexamethyl biguanide and propamidine.
Topics: Acanthamoeba; Acanthamoeba Keratitis; Adolescent; Adult; Animals; Antiprotozoal Agents; Benzamidines | 1997 |
Polyhexamethylene biguanide treatment for Acanthamoeba keratitis.
Topics: Acanthamoeba; Acanthamoeba Keratitis; Animals; Anti-Bacterial Agents; Biguanides; Disinfectants; Dru | 1998 |
Ultrastructural changes of Acanthamoeba cyst of clinical isolates after treatment with minimal cysticidal concentration of polyhexamethylene biguanide.
Topics: Acanthamoeba; Acanthamoeba Keratitis; Animals; Biguanides; Disinfectants; Drug Resistance; Humans; M | 1998 |
Is polyhexamethylene biguanide alone effective for Acanthamoeba keratitis?
Topics: Acanthamoeba; Acanthamoeba Keratitis; Administration, Topical; Adult; Animals; Biguanides; Cornea; D | 1998 |
Acanthamoeba keratitis in New Zealand, including two cases with in vivo resistance to polyhexamethylene biguanide.
Topics: Acanthamoeba; Acanthamoeba Keratitis; Adult; Animals; Biguanides; Contact Lens Solutions; Contact Le | 1998 |
Treatment of Acanthamoeba keratitis combined with fungal infection with polyhexamethylene biguanide.
Topics: Acanthamoeba Keratitis; Adult; Biguanides; Disinfectants; Eye Infections, Fungal; Fungi; Humans; Mal | 1999 |
The reculture technique: individualizing the treatment of Acanthamoeba keratitis.
Topics: Acanthamoeba; Acanthamoeba Keratitis; Adolescent; Adult; Animals; Antiprotozoal Agents; Benzamidines | 2000 |
Therapy of acanthamoeba keratitis--an experimental study.
Topics: Acanthamoeba Keratitis; Animals; Biguanides; Female; Fluconazole; Male; Neomycin; Povidone-Iodine; R | 2000 |
Polyhexamethylene biguanide (0.02%) alone is not adequate for treating chronic Acanthameoba keratitis.
Topics: Acanthamoeba Keratitis; Biguanides; Chronic Disease; Disinfectants; Humans; Treatment Failure | 2000 |
Coexistent adenoviral keratoconjunctivitis and Acanthamoeba keratitis.
Topics: Acanthamoeba; Acanthamoeba Keratitis; Acyclovir; Adenovirus Infections, Human; Adenoviruses, Human; | 2000 |
Development and application of an in vitro susceptibility test for Acanthamoeba species isolated from keratitis to polyhexamethylene biguanide and chlorhexidine.
Topics: Acanthamoeba; Acanthamoeba Keratitis; Animals; Biguanides; Chlorhexidine; Disinfectants; Dose-Respon | 2002 |
[Acanthamoeba keratitis treated with propamidine and polyhexamethyl biguanide (PHMB)].
Topics: Acanthamoeba Keratitis; Amebicides; Benzamidines; Biguanides; Contact Lenses; Disinfectants; Drug Th | 2002 |
Treatment of Acanthamoeba keratitis with polyhexamethylene biguanide.
Topics: Acanthamoeba; Acanthamoeba Keratitis; Adult; Aged; Animals; Anti-Bacterial Agents; Biguanides; Drug | 1992 |